Argenx SE announced that its ARGX-119 therapy is advancing to a registrational study in CMS.
1 report, 1 independent
Updated Jul 31
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Argenx SE announced that its ARGX-119 therapy is advancing to a registrational study in CMS.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Centers for Medicare and Medicaid Services
United States federal agency
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireargenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update $949 million in second quarter global product net sales VYVGART SC launch in CIDP progresses with more than